Key result
This review highlights the paucity of data and heterogeneity in outcomes regarding the medical management and revascularization strategies for CAD and ACS in patients with chronic kidney disease.
This review highlights the challenges and current evidence regarding the medical and interventional management of CAD and ACS in patients with CKD, a population often excluded from major trials.
Data limitations preclude firm CAD/ACS recommendations in CKD; leaves open the need for inclusive prospective trials.
Coronary Artery Disease (CAD) is a large contributor to morbidity and mortality in the chronic kidney disease (CKD) and end-stage renal disease (ESRD) population. Due to the fact that many large-scale trials evaluating management for acute coronary syndromes (ACS) and CAD have excluded patients with CKD, there is a paucity of data investigating medical management of CAD and revascularization strategies of these patients. Further, while there have been many advances in the treatment for ACS and CAD, both medically and technologically, few studies have focused on the CKD population and many predate these advancements in management. Newer studies that include CKD patients have shown heterogeneity in various outcomes, making management decisions challenging. In this review, we summarize the epidemiologic significance of ACS and CAD in patients with CKD, discuss the diagnosis of ACS in this patient population, and review the therapeutic interventions in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Lingel et al. (2017) conducted a review in Coronary artery disease and acute coronary syndrome in chronic kidney disease. Therapeutic interventions for CAD and ACS was evaluated. This review highlights the paucity of data and heterogeneity in outcomes regarding the medical management and revascularization strategies for CAD and ACS in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: